Sign in Create account

Lasa Supergenerics Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 540702
₹5.67
▼ -0.29 (-4.87%)
Sept. 28, 2026 · BSE · bse_bhavcopy
Quality
27/100
Weak
Valuation
—/100
Data unavailable
Momentum
40/100
Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-80.1
Free Cash Flow
₹-23 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
116.82%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
58.51%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-95.17%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-146.51%
as of Dec. 31, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-93.87%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.62
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.20
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-30.22
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
-116.19%
as of Dec. 31, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-271.83%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-236.75%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-3.85%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-22.33%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-13.18%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.20)
  • No Return on equity is 15% or more (-13.2%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 4 met
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-4.9%
Low 5.6700 · High 5.7000
1W return
-4.9%
Low 5.6700 · High 5.7000
1M return
-18.2%
Low 5.6700 · High 7.2800
52W return
-80.1%
Low 5.6700 · High 8.4200
Lifetime High ₹207.6500 (Jan. 3, 2018)
Lifetime Low ₹5.6700 (Sept. 28, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
6.1
10D
6.5
20D
7.8
50D
12.6
100D
17.4
200D
24.2

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
90.4%
Month avg. delivery
87.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

5.68
Pivot
First resistance5.69
Second resistance5.71
Third resistance5.72
First support5.66
Second support5.65
Third support5.63
Day RSI21.1
Day MFI60.3
Day MACD-2.17
Day MACD signal-2.61

Beta

1M—
3M-2.03
1Y-2.03
3Y0.72

Price change analysis

↓ -18.2%
Over 1 Month
LowHigh
5.677.28
↓ -80.1%
Over 3 Months
LowHigh
5.678.42
↓ -80.1%
Over 6 Months
LowHigh
5.678.42
↓ -80.1%
Over 1 Year
LowHigh
5.678.42
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹1 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.7100

Ranks #None of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Mar 2026
  • Promoter53.65%

Largest holders

NameCategoryShares %Shares
OMKAR PRAVIN HERLEKARPromoter53.6500%26879650
MAHENDRA GIRDHARILAL WADHWANIPublic1.0000%501013

As of March 31, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 53.65% in Mar 2026 qtr

Historical fii holding

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 54 insider trades, 0 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
10 Apr 2023 Shivanand Gajanan Hegde Director Buy 0 ₹0
10 Apr 2023 Omkar Herlekar Promoter Buy 0 ₹0
10 Apr 2023 Vineeta Hitesh Wadhwani Other Buy 0 ₹0
10 Apr 2023 Vineeta Hitesh Wadhwani Other Sell 0 ₹0
1 Jul 2022 Omkar Herlekar Promoter Pledge Invoke 0 ₹2.06 Cr
5 Feb 2022 Omkar Herlekar Promoter Pledge Invoke 0 ₹16.10 Cr
23 Dec 2019 Omkar Pravin Herlekar Other Buy 0 ₹0
21 Jun 2018 Omkar Pravin Herlekar Promoter Buy 0 ₹0
21 Jun 2018 PRAVIN HERLEKAR Immediate relative Sell 0 ₹0
3 May 2018 OMKAR SPECIALITY CHEMICALS LIMITED Others Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 5 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
8 Sep 2025 AMIT KUMAR JAIN HUF Bulk Buy 398,113 10.5700 NSE
8 Sep 2025 AMIT KUMAR JAIN HUF Bulk Sell 224,606 10.6500 NSE
25 Aug 2021 SHREE VASUDEV EXIM Bulk Buy 338,428 81.8500 BSE
24 Aug 2021 SHREE VASUDEV EXIM Bulk Sell 50,510 80.2700 BSE
24 Aug 2021 SHREE VASUDEV EXIM Bulk Buy 269,761 80.4500 BSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
16 Sep 2022 Annual General Meeting/Dividend - Re 0.25 Per Share 0.2500 —
15 Sep 2021 Annual General Meeting/Dividend - Rs 0.25 Per Share 0.2500 —

Corporate Actions

Full history (7 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
20 Sep 2024OTHERAnnual General Meeting
20 Sep 2023OTHERAnnual General Meeting
17 Sep 2020OTHER Annual General Meeting
19 Sep 2019OTHER Annual General Meeting
17 Sep 2018OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
14 Aug 2026 Financial Results Yes
29 May 2026 Financial Results Yes
13 Feb 2026 Financial Results Yes
14 Nov 2025 Financial Results Yes
13 Aug 2025 Financial Results Yes

Corporate Announcements

All 428 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Lasa Supergenerics Ltd - 540702 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct 2026 Shareholders meeting Lasa Supergenerics Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.
30 Sep 2026 AGM/EGM Lasa Supergenerics Ltd - 540702 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 Shareholders meeting Lasa Supergenerics Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
28 Sep 2026 Insider Trading / SAST Lasa Supergenerics Ltd - 540702 - Closure of Trading Window
28 Sep 2026 Trading Window Lasa Supergenerics Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
19 Sep 2026 Others Lasa Supergenerics Ltd - 540702 - Reg. 34 (1) Annual Report.
9 Sep 2026 Company Update Lasa Supergenerics Ltd - 540702 - Notice Of The Annual General Meeting
9 Sep 2026 Others Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Outcome Of The Baord Meeting
9 Sep 2026 General Updates Lasa Supergenerics Limited has informed the Exchange about General Updates

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.20)

Weaknesses

  • Low Return on Equity (-13.2%)
  • Thin net profit margin (-116.2%)
  • Tight liquidity (Current Ratio 0.62)
  • Declining revenue YoY (-93.9%)
  • Declining profit YoY (-146.5%)

Opportunities

  • RSI in oversold territory (21.1) -- a technical rebound zone

Threats

  • Down 80.1% over the past year
  • Weak interest coverage (-30.2x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Lasa Supergenerics Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.